Introduction
Thyroid hormone (T3) resistance is inherited in most cases in an autosomal dominant manner. The disorder is characterized by elevated free thyroid hormone levels and partial resistance to thyroid hormone at the cellular level. Distinct single amino acid substitutions in the ligand binding domain of the ft form of the thyroid hormone receptor have been described in two kindreds with this disorder. We used transient expression assays to characterize the functional properties of these receptor mutants, one containing a Gly to Arg change at amino acid 340 (G340R) and the other a Pro to His change at amino acid 448 (P448H). A nine amino acid carboxy terminal deletion (A448456), analogous to an alteration that occurs in v-erbA, was also studied for comparison with the mutations that occur in the T3 resistance syndrome. None of the receptor mutants were able to mediate thyroid hormone dependent activation (TreTKCAT) or repression (TSHaCAT) of reporter genes when compared with the wild type receptor. In addition, the mutants inhibited the activity of normal a and (3 receptor isoforms when examined in coexpression assays. This activity, referred to as dominant negative inhibition, was manifest with respect to both the positively and negatively regulated reporter genes. Although mutant receptor binding to DNA was unaffected, ligand binding studies showed that the G340R and A448456 mutants failed to bind T3, whereas the P448H mutant bound hormone with reduced affinity (-10% of normal) compared to the wild type receptor. Consistent with this finding, the P448H mutant receptor was partially active at higher T3 concentrations. Furthermore, the dominant negative inhibition elicited by the P448H receptor mutant at higher T3 concentrations was reversed in the presence of high doses of T3. These findings indicate that mutant (3 receptors in patients with thyroid hormone resistance have reduced affinity for T3 and are functionally deficient, but impair the activity of normal receptors, thereby providing a mechanism for the dominant mode of inheritance in this disorder. (J. Clin. Invest. 1991 Invest. . 87:1977 Invest. -1984 .) Key words: transcriptional regulation -erbAthyroid-stimulating hormone -thyroid hormone resistance * thyroid hormone V. K. K. Chatterjee and T. Nagaya contributed equally to this work.
The syndrome of generalized thyroid hormone resistance (GTHR)' was first described by Refetoff et al. (1) , and is characterized by elevated circulating levels of free thyroxine (T4) and triiodothyronine (T3) and inappropriately normal or increased levels of thyroid-stimulating hormone (TSH). Although patients with GTHR are relatively refractory to the metabolic effects of increased thyroid hormone, there is variability in the degree of resistance in different target tissues within an individual and the clinical phenotype varies in different kindreds (2) . An autosomal recessive mode of inheritance was suggested in original GTHR kindred, but the disorder has been shown to segregate in an autosomal dominant manner in most families (1, 3) .
Although both quantitative (4) and qualitative defects (5) in thyroid hormone binding to fibroblast nuclear receptors from GTHR patients have been described, these studies did not firmly establish a defect at the level of the thyroid hormone receptor. Recently, two thyroid hormone receptor genes, designated hTRa and hTR#, have been identified, encoding highly homologous proteins with different tissue distributions (6, 7) . Genetic analysis has now shown linkage between the GTHR syndrome and the (3 receptor gene locus in three kindreds (8, 9) . These observations have been extended by sequencing (3 receptor cDNAs from two separate families with the disorder. In both cases, affected individuals have a point mutation in one allele of the (3 receptor gene together with a second normal allele, whereas their unaffected relatives have two normal alleles. In each kindred, the point mutation alters a single amino acid codon in the carboxy-terminal ligand binding domain of the receptor. In one kindred, the mutation is a Glycine to Arginine substitution at amino acid 340 (G340R) (10) . In the other kindred, a Proline to Histidine substitution was identified at amino acid 448 (P448H) (9) .
Although ligand binding studies have shown that these mutant proteins either fail to bind T3 (10) or bind hormone with reduced affinity (11) , their ability to modulate target gene expression has yet to be defined. Moreover, because the affected individuals also possess a second normal (3 receptor allele and presumably two normal a receptor alleles, the mechanism by which the mutant receptor causes resistance to thyroid hormone action is unclear. It has been hypothesized that the mutant receptor might block the activity of normal receptors (9, 10) . In support of this concept, receptor homologues (v-erbA; splicing variant a2) that are unable to bind thyroid hormone have been shown to inhibit the action ofthe wild type receptors (12) (13) (14) .
Transient expression assays provide a convenient model for examining the functional properties ofthyroid hormone receptors. We have previously used a receptor deficient human cell line (JEG-3) for studies ofthe functional properties ofhuman a and ,3 receptor isoforms (15, 16) . Both types of thyroid hormone receptor are capable of activating expression of a reporter gene (TreTKCAT) that contains a palindromic -positive TRE (TREp) and repressing the activity of a reporter gene (TSHaCAT) that contains a negative thyroid response element (nTRE) (15, 16) . Transcriptional stimulation and repression each require receptor activation by thyroid hormone.
In this study, we used this transient assay system to characterize the functional properties of the mutant receptors from two GTHR kindreds (G340R and P448H) as well as a carboxyterminal truncated form of the 1B receptor (A448-456) that corresponds to the deletion in v-erbA (13) . We demonstrate that in addition to being nonfunctional, the receptor mutants inhibit the action oftheir wild type receptor counterparts. This dominant negative action by the mutant receptors may explain the dominant mode of inheritance as well as resistance to hormone action.
Methods
Plasmid constructions and receptor mutagenesis. (14) . The mutations are illustrated schematically in Fig. 1 (19) , fresh serum-stripped media were added with or without T3. After an additional 48 h, the cells were harvested and CAT enzyme activity was measured by quantitating the acetylation of ["Clchloramphenicol (20) . The (15) were annealed, and the 3' recessed ends were filled in with biotin-I l-dUTP (Enzo Biochem, Inc., New York, NY), dATP, dCTP, and dGTP using Klenow polymerase. Biotinylated DNA (500 fmol) was incubated with
[35S]methionine labelled receptor (100,000 cpm of TCA precipitable protein) for 40 min at 240C. The receptor-DNA complexes were precipitated with streptavidin-agarose beads (Bethesda Research Laboratories, Gaithersburg, MD) and quantitated by scintillation counting.
Receptor interactions with DNA were also analyzed usinggel mobility shift assays in which nuclear receptor extracts were prepared from COS-I cells (16 (Fig. 2 A) (Fig. 4 A) . Similarly, the degree of repression of TSHaCAT was reduced from 62% with wild type receptor alone to 30% with a 10-fold excess ofG340R (Fig. 4 B) . In both cases, half-maximal inhibition of wild type receptor activity occurred using a four to fivefold excess of mutant receptor.
A B Receptor Ratio P-G3 aR The human a isoform of the thyroid hormone receptor is highly homologous (> 85%) to the ,3 receptor in the central DNA binding and carboxy-terminal ligand binding domains (Fig. 1 A) . Consonant with this observation, the a receptor isoform binds T3 and can activate and repress target reporter genes in JEG-3 cells in a manner similar to the ft receptor (12, 16) . To test the ability of the mutant receptors to inhibit wild type a receptor activity, experiments analogous to those with the f3 receptor were performed (Fig. 5) . T3-dependent activation of TreTKCAT by the a receptor was reduced from 118-fold to 36-and 43-fold with the G340R and P448H mutants, respectively. A448-456 was a more potent inhibitor and reduced stimulation to 11-fold. The receptor mutants were less effective in their inhibition of T3 dependent suppression by a receptor. After treatment with T3, TSHaCAT was repressed by 84% in the presence of a receptor alone and the degree of repression was reduced to 61%, 64%, and 43% in the presence of excess G340R, P448H, and A448-456 mutants, respectively.
Ligand and DNA binding properties of the receptor mutants. As shown in the foregoing experiments, the mutant receptors exhibited somewhat different functional properties. When tested alone, the P448H mutant was capable ofmodulating target gene activity slightly, whereas G340R and A448-456 were completely inactive (Fig. 2) . Likewise, when listed in order of potency as dominant negative inhibitors of wild type receptor activity (Fig. 3, 5) , the rank order was A448-456>G340R>P448H. One potential explanation for these results could involve differences amongst the receptors in their ligand binding properties. Therefore, each of the receptors was generated by in vitro transcription and translation to allow measurements of the affinity of T3 binding (Table I ). The wild type receptor binding affinity (1.46 X 10" M-') was similar to values reported previously (21) . The P448H mutant bound T3, but with an affinity that was reduced by a log order (1.52 X 109 M-l). Binding to G340R and A448-456 mutants, if it occurs, was below detection in these assays.
Two different assays were employed to assess the ability of receptor mutants to bind to DNA. In the ABCD binding assay,
[35S]methionine-labelled receptors were prepared by in vitro translation, and binding of labelled receptors to biotinylated DNA was measured after precipitation with streptavidin agarose beads (Fig. 6 A) . Using a known receptor binding site (TREp), the binding of each of the ligand domain receptor mutants (G340R, P448H, A448-456) was comparable to that of the wild type A receptor, whereas a mutation in the DNA binding domain ofthe # receptor (C122S) (15) resulted in negligible interaction with TREp.
Receptors were also expressed in COS-1 cells and used to assess DNA binding properties using gel mobility shift assays (Fig. 6 B) The dominant negative effects of the P448H receptor mutant were also dependent on T3 concentration (Fig. 7) . TreTK (14, 26) . In support of this concept, the thyroid hormone receptor has recently been shown to form heterodimers with the. retinoic acid receptor via a shared structural motif within the carboxy-terminal region (27) . Both of the GTHR receptor mutations occur outside of this putative dimerization domain, raising the possibility that they could still form dimers. Further structure-function analyses within this region will be required to precisely delineate the receptor sequences that are required for receptor-receptor interactions.
A second mechanism for dominant negative activity would be for the transcriptionally defective mutants to compete with the wild type receptor for binding to a common DNA target sequence, which in this case is the TRE (Fig. 8, model 2) . The finding that a mutation in the DNA binding domain of the viral oncogene, v-erbA, abolishes its dominant negative properties, lends support to this type of mechanism (13 The mutant receptors could also inhibit the action of normal receptors by sequestering a shared accessory factor that is necessary for wild type receptor modulation of gene transcription (Fig. 8, model 3 ). This property, sometimes referred to as "squelching" (29) , has been postulated to explain transcriptional interference between coexpressed estrogen and progesterone receptors (30) , and recent analyses of transcriptional regulation by the adenovirus Ela protein also support this concept (31 We examined the issue of the stoichiometry of mutant receptor inhibition in vitro by altering the ratio ofmutant to wild type receptors in transient expression assays (Fig. 4) . Although some degree ofdominant negative activity was apparent at low mutant/wild type receptor ratios (1:1 or 2:1), it was somewhat surprising that 50% inhibition required at least a fourfold excess of mutant receptor. The basis for the requirement for excess mutant receptor and its relevance to clinical thyroid hormone resistance are unclear. It is possible that clinical measurements of resistance (e.g., elevated thyroid hormone levels) are more sensitive indicators of receptor inhibition than our in vitro assays oftransient gene expression. A more likely basis for the requirement for excess mutant receptor may involve the artificial nature of the transient expression assay. Although the predicted ratios of expressed receptor are likely to correlate with the amounts of transfected plasmid, we do not have a quantitative measure of the expressed receptor proteins. Based upon their levels of expression in transfected COS cells (Fig. 6  B) , there is some evidence that the stabilities ofthe mutant and wild type receptor mRNAs and proteins are similar in transfected cells. It is possible that quantitative differences in dominant negative activity would be found under different conditions such as performing the experiments at a lower or higher level ofexpressed reporter gene or using a different level ofwild type receptor. In addition, the current studies have been performed in only a single receptor deficient cell line (JEG-3 cells). A number of recent reports indicate that T3 receptors interact with other cellular proteins (27, (39) (40) (41) and the levels and compositions of such factors may alter dominant negative regulation in a cell type specific manner. One must also consider that the inhibitory effects of the mutant receptors may be dependent upon the target gene for thyroid hormone receptor action. For example, coexpressed thyroid hormone and retinoic acid receptors act cooperatively to induce the expression of a target gene containing a palindromic TRE, but inhibit the expression of a gene containing TREs from the myosin heavy chain gene (27) . Because of these issues, it is apparent that one should interpret transient receptor assays of receptor function cautiously, particularly with respect to quantitative effects. Despite these reservations, this technique appears to provide a valuable in vitro assay for the transcriptional activity of receptor mutants and to serve as an index of dominant negative activity.
The observation that different kindreds with GTHR display distinct clinical features is a particularly intriguing aspect of this disorder (2, 3, 9) . We have shown that the receptor mutants from two kindreds differ in their functional properties. At a low T3 concentration, the properties of P448H and G340R are essentially indistinguishable in vitro. However, at a T3 concentration which saturates P448H, this mutant is transcriptional active and loses its dominant negative activity. However, we note that individuals with the P448H mutation (9) and the G340R mutation (10) have similar circulating thyroid hormone levels and the clinical features of resistance are different, but not necessarily less severe, in individuals with the P448H mutation. Thus, it is unclear at this stage whether differences in ligand affinity or some other aspect of mutant receptor function account for phenotypic differences in this disorder. To better understand the clinical features that result from thyroid hormone resistance, it will be necessary to acquire more information about the in vivo distribution, regulation, and mechanisms of action of normal and mutant receptors. Recent studies (9, 42) suggest that a number of different mutations may exist in other kindreds with GTHR. Analyses of their functional properties will be of interest to further elucidate the pathophysiology of this disorder.
